These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8439917)

  • 1. Report calls for major changes in drug-approval process, but will they be implemented?
    Robinson A
    CMAJ; 1993 Feb; 148(3):432-5. PubMed ID: 8439917
    [No Abstract]   [Full Text] [Related]  

  • 2. A proposal for radical changes in the drug-approval process.
    Wood AJ
    N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 4. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing prescription medications for priority regulatory review.
    Rawson NS
    Regul Toxicol Pharmacol; 2005 Jun; 42(1):70-6. PubMed ID: 15896445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The process of evaluating and regulating a new drug: phases of a drug study.
    Cowan CC
    AANA J; 2002 Oct; 70(5):385-90. PubMed ID: 12425128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approval process and access to prescription drugs in Canada.
    Marra CA; Lynd LD; Anis AH; Esdaile JM
    Arthritis Rheum; 2006 Feb; 55(1):9-11. PubMed ID: 16463404
    [No Abstract]   [Full Text] [Related]  

  • 9. Proposals to speed up European drug approval process questioned.
    Illman J
    J Natl Cancer Inst; 2001 Nov; 93(22):1682-3. PubMed ID: 11717325
    [No Abstract]   [Full Text] [Related]  

  • 10. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
    Rawson NS; West R; Appel WC
    Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missing evidence.
    Hayes WS
    MLO Med Lab Obs; 2008 Oct; 40(10):68. PubMed ID: 18988559
    [No Abstract]   [Full Text] [Related]  

  • 14. Canada signs agreements to potentially share drug information with the US and Australia.
    Blouin D
    CMAJ; 2004 Jul; 171(2):121. PubMed ID: 15262871
    [No Abstract]   [Full Text] [Related]  

  • 15. [The precautionary principle, research and drugs].
    Joly P
    Bull Acad Natl Med; 2000; 184(5):931-6. PubMed ID: 11077714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [From an idea to a completed drug: a process of 10-15 years].
    Hacksell U; Johnsson G
    Lakartidningen; 1997 Jul; 94(28-29):2561-6. PubMed ID: 9254325
    [No Abstract]   [Full Text] [Related]  

  • 17. National panel studies approval process for AIDS & cancer drugs.
    Dimens Crit Care Nurs; 1990; 9(2):66. PubMed ID: 2328642
    [No Abstract]   [Full Text] [Related]  

  • 18. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R; Harris J; Wadhwa S; Chambers W
    Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing the progression of Alzheimer disease: methodologic issues.
    Leber P
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S10-21; discussion S37-9. PubMed ID: 9348423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(105):37988-98. PubMed ID: 12049094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.